QQ客服 官方微博 反馈留言

	Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial
	Yang, Lu; Yang, Sheng; Liu, Yutao; Li, Junling; Hu, Xingsheng; Wang, Yalei; Zhang, Yan; Wang, Yan
	2018
卷号	9期号:6页码:693-698
关键词	Acquired resistance EGFR-tyrosine kinase inhibitors non-small cell lung cancer phase II study TS-1
ISSN号	1759-7706
DOI	10.1111/1759-7714.12632
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6360328
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Yang, Lu,Yang, Sheng,Liu, Yutao,et al. Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial[J],2018,9(6):693-698.
APA	Yang, Lu.,Yang, Sheng.,Liu, Yutao.,Li, Junling.,Hu, Xingsheng.,...&Wang, Yan.(2018).Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial.,9(6),693-698.
MLA	Yang, Lu,et al."Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial".9.6(2018):693-698.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。